Home > Publications Database > Vitamin D3 deficiency and osteopenia in spastic paraplegia type 5 indicate impaired bone homeostasis. > print

001     268774
005     20240419133852.0
024 7 _ |a pmc:PMC10973513
|2 pmc
024 7 _ |a 10.1038/s41598-024-53057-5
|2 doi
024 7 _ |a pmid:38538623
|2 pmid
037 _ _ |a DZNE-2024-00318
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Ehnert, Sabrina
|b 0
245 _ _ |a Vitamin D3 deficiency and osteopenia in spastic paraplegia type 5 indicate impaired bone homeostasis.
260 _ _ |a [London]
|c 2024
|b Macmillan Publishers Limited, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1712654823_12206
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Hereditary spastic paraplegia type 5 (SPG5) is an autosomal recessively inherited movement disorder characterized by progressive spastic gait disturbance and afferent ataxia. SPG5 is caused by bi-allelic loss of function mutations in CYP7B1 resulting in accumulation of the oxysterols 25-hydroxycholesterol and 27-hydroxycholesterol in serum and cerebrospinal fluid of SPG5 patients. An effect of 27- hydroxycholesterol via the estrogen and liver X receptors was previously shown on bone homeostasis. This study analyzed bone homeostasis and osteopenia in 14 SPG5 patients as a non-motor feature leading to a potential increased risk for bone fractures. T-Scores in CT bone density measurements were reduced, indicating osteopenia in SPG5 patients. Further, we analyzed various metabolites of bone homeostasis by ELISA in serum samples of these patients. We identified a lack of vitamin D3 metabolites (Calcidiol and Calcitriol), an increase in Sclerostin as a bone formation/mineralization inhibiting factor, and a decrease in cross-linked N-telopeptide of type I collagen (NTX), a marker indicating reduced bone resorption. As statin treatment has been found to lower oxysterol levels, we evaluated its effect in samples of the STOP-SPG5 trial and found atorvastatin to normalize the increased sclerostin levels. In summary, our study identified osteopenia as a non-motor feature in SPG5 and suggests the need for vitamin D3 substitution in SPG5 patients. Sclerostin may be considered a therapeutic target and biomarker in upcoming therapeutical trials in SPG5.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Oxysterols
|2 NLM Chemicals
650 _ 7 |a Vitamin D
|0 1406-16-2
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Mutation
|2 MeSH
650 _ 2 |a Spastic Paraplegia, Hereditary: genetics
|2 MeSH
650 _ 2 |a Spastic Paraplegia, Hereditary: metabolism
|2 MeSH
650 _ 2 |a Oxysterols
|2 MeSH
650 _ 2 |a Paraplegia
|2 MeSH
650 _ 2 |a Homeostasis
|2 MeSH
650 _ 2 |a Vitamin D: therapeutic use
|2 MeSH
700 1 _ |a Hauser, Stefan
|0 P:(DE-2719)2810998
|b 1
|u dzne
700 1 _ |a Hengel, Holger
|0 P:(DE-2719)2811940
|b 2
700 1 _ |a Höflinger, Philip
|0 P:(DE-2719)2813301
|b 3
|u dzne
700 1 _ |a Schüle, Rebecca
|0 P:(DE-2719)2812018
|b 4
|u dzne
700 1 _ |a Lindig, Tobias
|b 5
700 1 _ |a Baets, Jonathan
|b 6
700 1 _ |a Deconinck, Tine
|b 7
700 1 _ |a de Jonghe, Peter
|b 8
700 1 _ |a Histing, Tina
|b 9
700 1 _ |a Nüssler, Andreas K
|b 10
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 11
|u dzne
700 1 _ |a Rattay, Tim
|0 P:(DE-2719)2811827
|b 12
|e Last author
|u dzne
773 _ _ |a 10.1038/s41598-024-53057-5
|g Vol. 14, no. 1, p. 7335
|0 PERI:(DE-600)2615211-3
|n 1
|p 7335
|t Scientific reports
|v 14
|y 2024
|x 2045-2322
856 4 _ |u https://pub.dzne.de/record/268774/files/DZNE-2024-00318%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/268774/files/DZNE-2024-00318.pdf
856 4 _ |u https://pub.dzne.de/record/268774/files/DZNE-2024-00318%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/268774/files/DZNE-2024-00318%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/268774/files/DZNE-2024-00318%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/268774/files/DZNE-2024-00318.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:268774
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810998
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811940
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2813301
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812018
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811827
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2024
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2023-08-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:11:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:11:06Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-24
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-24
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-24
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:11:06Z
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)1210016
|k AG Hauser
|l Advanced cellular models of neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1210016
980 _ _ |a I:(DE-2719)5000005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21